PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PDS Biotechnology to present updated data from the VERSATILE-002 trial on September 14, 2024, at the ESMO Congress 2024 in Barcelona, evaluating first-line treatment with Versamune® HPV in combination with KEYTRUDA® for HPV16-positive recurrent/metastatic HNSCC.
Reference News
PDS Biotechnology to present updated data from the VERSATILE-002 trial at the ESMO Congress 2024, evaluating Versamune® HPV in combination with KEYTRUDA® for HPV16-positive recurrent/metastatic HNSCC.
PDS Biotechnology to present updated data from the VERSATILE-002 trial on September 14, 2024, at the ESMO Congress 2024 in Barcelona, evaluating first-line treatment with Versamune® HPV in combination with KEYTRUDA® for HPV16-positive recurrent/metastatic HNSCC.
PDS Biotechnology to present updated data from the VERSATILE-002 trial on September 14, 2024, at the ESMO Congress 2024 in Barcelona, evaluating first-line treatment with Versamune® HPV in combination with KEYTRUDA® in HPV16-positive recurrent/metastatic HNSCC.